Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

CPHC, PROT, CAJ, CMN - Businesses Catching Attention by Stock-PR.com

 

Stock-PR Reporting

stockpr_logo-site

 

 

FREE Daily Stock Alerts From Stock-PR.com

 

 

chartstockalert

________________________________________

 

Proteonomix, Inc. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, disclosed further developments with Proteonomix's Joint Venture Company, XGEN Medical LLC ("XGen") towards implementing operations in the United Arab Emirates (U.A.E.). Proteonomix is the majority shareholder in XGen with the balance held by an anonymous investor group. Proteonomix personnel were on the ground in the U.A.E. over the past weeks to work together with the Investor Group through the start up phase. To date, XGen has established an office in the Monarch Office Tower on the prestigious Sheikh Zayed Road, and a residence for visiting Proteonomix personnel on Jumeira 2.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (NYSE:CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of Proteonomix's technologies.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

A subsidiary of Canon Inc. (NYSE:CAJ), Canon U.S.A., Inc., a leader in digital imaging solutions, previewed the CR-2 Digital Non-Mydriatic Retinal Camera at Vision Expo West. In addition to the CR-2 retinal camera, which is awaiting FDA clearance, Canon will showcase its current complete line of ophthalmic solutions at Vision Expo West, in the Canon booth at the Sands Expo Center in Las Vegas, October 7th – 9th, 2010.

Weighing only 33 pounds, the CR-2 Digital Non-Mydriatic Retinal Camera has a light, more compact leading-edge design, resulting in an intuitive instrument that is easy to use. The CR-2 retinal camera can be easily installed and takes up minimal office space or for added convenience, can be easily transported when needed. The illuminated control panel allows medical staff to navigate operations in darkened rooms. Contributing to a lower total-cost-of-ownership, the CR-2 retinal camera’s energy-efficient design with white LED for flash intensity improves maintenance and uses less power, helping to reduce energy costs in medical facilities.

Canon U.S.A., Inc., is a leading provider of consumer, business-to-business, and industrial digital imaging solutions. Its parent company, Canon Inc. (NYSE:CAJ), a top patent holder of technology, ranked fourth overall in the U.S. in 2009†, with global revenues of US $35 billion, is listed as number six in the computer industry on Fortune Magazine's World’s Most Admired Companies 2010 list, and is on the 2009 BusinessWeek list of "100 Best Global Brands." Canon U.S.A. is committed to the highest levels of customer satisfaction and loyalty, providing 100 percent U.S.-based consumer service and support for all of the products it distributes. At Canon, we care because caring is essential to living together in harmony. Founded upon a corporate philosophy of Kyosei – "all people, regardless of race, religion or culture, harmoniously living and working together into the future" – Canon U.S.A. supports a number of social, youth, educational and other programs, including environmental and recycling initiatives.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Cantel Medical Corp. (NYSE:CMN), through its Mar Cor Purification subsidiary, has continued the expansion of Cantel Medical's Water Purification and Filtration segment by acquiring the exclusive rights in the United States to manufacture and sell Gambro's water treatment products used in the production of water for hemodialysis. The total consideration for the transaction with Gambro was $23.75 million and the licensed business had pre-acquisition revenues of approximately $14 million. This transaction is expected to be slightly accretive to Cantel Medical's earnings per share in the first full year. Mar Cor will immediately commence sales and service of all Gambro water products, components, parts and consumables solely intended for the U.S. market. The manufacturing of these products will be transitioned into Mar Cor's ISO 13485 Registered Medical Device manufacturing facility in Plymouth, MN. Mar Cor will provide service and support to Gambro's installed base of over 1,200 clinics and hospitals in the United States. All U.S. employees aligned with Gambro's water business will be offered employment with Mar Cor, which will help provide a smooth transition for all Gambro customers.

Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Cantel Medical's products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. Cantel Medical also provides technical maintenance for Cantel Medical's products and offer compliance training services for the transport of infectious and biological specimens.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Canterbury Park Holding Corporation (NASDAQ:CPHC) released results for the second quarter and six months ended June 30, 2010. Canterbury Park Holding Corporation reported a net loss of $380,969 on revenues of $11,453,879 for the three months ended June 30, 2010, compared to a net loss of $173,099 on revenues of $11,174,591 for the same period in 2009. For the six months ended June 30, 2010, the net loss was $1,020,610 on revenues of $19,242,492 compared to net income of $143,675 on revenues of $19,386,113 for the same six month period in 2009. The loss for the six month period was largely attributable to a one-time, first quarter charge of $909,540 related to the disposal of assets in connection with the renovation of Canterbury Park Holding's Card Casino. The diluted loss per share for the 2010 second quarter was $.09 compared to diluted loss per share of $.04 for the second quarter of 2009, and the diluted loss per share for the six months ended June 30, 2010 was $.25 compared to diluted earnings per share of $.04 for the same six month period in 2009.

Canterbury Park Holding hosts pari-mutuel wagering and card games at its facility in Shakopee, Minnesota. Pari-mutuel wagering is offered on live thoroughbred and quarter horse races each summer, and simulcast wagering on races held at out-of-state racetracks is available year-round. Canterbury Park Holding's Card Casino hosts a variety of poker and casino style table games 24 hours a day. Canterbury Park Holding also derives revenues from related services and activities, such as concessions, parking, programs, and from other entertainment events held at the facility.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (OTCPK:PROT).

Sign Up For Free Stock Alerts At http://stock-pr.com/signup

http://stock-pr.com/img/stock-pr_buscard.jpg

________________________________________

Be Sure To Visit stock-pr.ning.com

**********************************************************************

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.